Clinical outcomes in people with type 2 diabetes and acute kidney disease: combined SGLT2i and GLP-1RA therapy vs. monotherapy
Authors' conclusion
Combined SGLT2i and GLP-1RA therapy offers better survival and kidney protection but requires careful monitoring for hypoglycemia and retinopathy.
Study context
- Population
- Adults with T2D and acute kidney disease (AKD) treated with SGLT2i, GLP-1 RA or both, 2012–2023, TriNetX
- Participants
- 29,269 adults
- Exposure
- Combined SGLT2i + GLP-1 RA therapy vs SGLT2i or GLP-1 RA monotherapy
- Outcome
- All-cause mortality, major adverse kidney events (MAKE) and MACE
Methodological detailsTriNetX
- TriNetX
Main finding
As reported in the abstract
All-cause mortality · mean follow-up 2.4 years
Adjusted hazard ratio
0.53
Combined vs SGLT2i
Adjusted hazard ratio
0.43
Combined vs GLP-1RAs
Observational data: associations, not effects.
Further findings
| Outcome | aHR |
|---|---|
| MAKE · mean follow-up 2.7 yearsCombined vs SGLT2i | 0.70 |
| MAKE · mean follow-up 2.7 yearsCombined vs GLP-1RAs | 0.45 |
Major adverse cardiovascular events (MACE)
- MACE risk was similar across groups
Safety
| Outcome | aHR |
|---|---|
| Hypoglycaemia and DRCombined vs SGLT2i · hypoglycaemia | 1.51 |
| Hypoglycaemia and DRCombined vs SGLT2i · diabetic retinopathy | 1.59 |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Clinical outcomes in people with type 2 diabetes and acute kidney disease: combined SGLT2i and GLP-1RA therapy vs. monotherapy. Diabetes Res Clin Pract. Published 26 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →